Drug Trial Radar · NCT07387549
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
May 14, 2026
Primary completion
Apr 30, 2031
Study completion May 31, 2031
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Feb 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out how well and safely elafibranor works compared to placebo in adult participants with Primary sclerosing cholangitis (PSC). PSC is a rare disease that causes inflammation and scarring of the bile ducts in the liver. Over time, this can lead to liver damage and serious health problems, including the need for a liver transplant and death. In this study, about 350 participants with large duct PSC will take part. Participants will be randomized to receive either elafibranor 120 mg once daily or a placebo (a tablet with no active medicine). The study includes a screening period, an treatment period, and a post-treatment safety follow-up. During the study, participants will undergo routine clinical assessments, laboratory testing, imaging evaluations, and complete patient-reassessments to evaluate liver disease progression, symptoms, quality of life and safety. Following the end of treatment, participants will complete a safety follow-up period at approximately four weeks. Participants may withdraw from the study at any time. Each participant may be in the study for several years, as the treatment period will continue until the study reaches enough health events among participants, which is expected to take about 5 years.
Conditions
- Primary Sclerosing Cholangitis
Interventions
ElafibranorDrug
Round and orange film coated tablet of 120 mg
PlaceboOther
Round and orange film coated tablet of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-Free SurvivalTime frame: From baseline until the end of treatment (estimated up to 5 years)
Locations
231 sites in 25 countries. Site status is shown where the registry gives one.
Arizona Liver Health
Chandler, Arizona · Recruiting
Mayo Clinic in Arizona
Phoenix, Arizona · Not yet recruiting
Southern California Research Center
Coronado, California · Recruiting
University of California San Diego
La Jolla, California · Not yet recruiting
Keck Medicine of USC - USC Healthcare Center 1
Los Angeles, California · Not yet recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Not yet recruiting
California Liver Research Institute
Pasadena, California · Recruiting
Stanford University
Redwood City, California · Not yet recruiting
University of California Davis Medical Center
Sacramento, California · Not yet recruiting
Sutter Health Van Ness Campus Medical Office Building
San Francisco, California · Not yet recruiting
University of California, San Francisco Medical Center
San Francisco, California · Recruiting
University of Colorado Hospital Anschutz Outpatient Pavilion
Aurora, Colorado · Not yet recruiting
Peak Gastroenterology Associates
Colorado Springs, Colorado · Recruiting
South Denver Gastroenterology,P.C.
Englewood, Colorado · Recruiting
Rocky Mountain Gastroenterology (RMG)
Littleton, Colorado · Recruiting
Yale Medical Group - Yale Digestive Diseases -Temple Medical Center Location
New Haven, Connecticut · Not yet recruiting
MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH)
Washington D.C., District of Columbia · Not yet recruiting
University of Miami - Schiff Center for Liver Diseases
Miami, Florida · Recruiting
Piedmont Hospital - Piedmont Transplant Institute
Atlanta, Georgia · Not yet recruiting
Northwestern Medicine
Chicago, Illinois · Not yet recruiting
Rush University Medical Center
Chicago, Illinois · Not yet recruiting
The University of Chicago Medicine
Chicago, Illinois · Not yet recruiting
Indiana University School of Medicine
Indianapolis, Indiana · Recruiting
Gastroenterology Health Partners, PLLC (Southern Indiana Location)
New Albany, Indiana · Not yet recruiting
Deaconess GI Specialty Center
Newburgh, Indiana · Not yet recruiting
The University of Iowa Hospitals & Clinics
Iowa City, Iowa · Recruiting
University Of Louisville School Of Medicine
Louisville, Kentucky · Not yet recruiting
Mercy Medical Center, Inc
Baltimore, Maryland · Recruiting
Johns Hopkins University School of Medicine
Baltimore, Maryland · Not yet recruiting
Massachusetts General Hospital
Boston, Massachusetts · Not yet recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Not yet recruiting
University of Michigan
Ann Arbor, Michigan · Not yet recruiting
Henry Ford Health System
Detroit, Michigan · Not yet recruiting
Mayo Clinic Cancer Center (MCCC) - Rochester
Rochester, Minnesota · Not yet recruiting
Saint Louis University
St Louis, Missouri · Not yet recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Not yet recruiting
NYU Langone Gastroenterology and Hepatology Associates
New York, New York · Not yet recruiting
Weill Medical College Of Cornell University
New York, New York · Not yet recruiting
Mount Sinai Medical Center
New York, New York · Not yet recruiting
University of Rochester Medical Center
Rochester, New York · Not yet recruiting
Showing 40 of 231 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.